Literature DB >> 1790569

Long-term results of migraine prophylaxis with flunarizine and beta-blockers.

C Wöber1, C Wöber-Bingöl, G Koch, P Wessely.   

Abstract

We followed-up 64 migraine patients after discontinuation of successful interval prophylaxis with flunarizine, propranolol or metoprolol, to investigate how long the therapeutic success would last, if further prophylaxis would be successful again, and what factors would influence the prognosis. We found that 16 out of 64 patients experienced a lasting reduction of migraine frequency, whereas 48 patients did improve initially, but later experienced a relapse. Further prophylaxis was effective in 29, poorly effective in 11, and ineffective in 8 of these patients; in 7 of the 8 non-responders prophylaxis was not changed. Negative prognostic factors were frequent attacks, a history of analgesic abuse and/or analgesic withdrawal therapy and ineffective previous prophylaxis. In conclusion, the therapeutic success decreases dramatically in the majority of patients several months after discontinuation of prophylaxis; further prophylaxis is more effective if the substance class is changed; increased analgesic intake is the most important prognostic factor. As a strategy for migraine prophylaxis we propose sequential changing of interval prophylaxis or--in patients with negative prognostic factors--long-term prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1790569     DOI: 10.1046/j.1468-2982.1991.1106251.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  12 in total

Review 1.  Prophylaxis of migraine headache.

Authors:  Tamara Pringsheim; W Jeptha Davenport; Werner J Becker
Journal:  CMAJ       Date:  2010-02-16       Impact factor: 8.262

Review 2.  Strategies for diagnosing and managing medication-induced headache.

Authors:  J G Edmeads; M J Gawel; J Vickers
Journal:  Can Fam Physician       Date:  1997-07       Impact factor: 3.275

3.  [Development of a screening tool for migraine prophylaxis].

Authors:  A Wissmann; A Feuersenger; A Gendolla; U Reuter; A Straube; S Evers; A May; A Peikert; V Pfaffenrath; H Staudenmayer; H-C Diener
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

4.  Effects of betaxolol and flunarizine on visual fields and intraocular pressure in patients with migraine.

Authors:  Alper Yarangümeli; Selçuk Comoglu; Ozlem Gürbüz Köz; Atilla Halil Elhan; Gülcan Kural
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 5.  Preventive Migraine Treatment.

Authors:  Stephen D Silberstein
Journal:  Continuum (Minneap Minn)       Date:  2015-08

6.  [Long-term efficacy and side effects of various migraine prophylactics: a retrospective analysis.].

Authors:  G Haag; F Mastrosimone; C Iaccarino; M J Müller
Journal:  Schmerz       Date:  1994-09       Impact factor: 1.107

Review 7.  Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification.

Authors:  James A Charles; B L Peterlin; Alan M Rapoport; Steven L Linder; Marielle A Kabbouche; Fred D Sheftell
Journal:  J Headache Pain       Date:  2009-06-09       Impact factor: 7.277

Review 8.  Overview of diagnosis and management of paediatric headache. Part II: therapeutic management.

Authors:  Cristiano Termine; Aynur Ozge; Fabio Antonaci; Sophia Natriashvili; Vincenzo Guidetti; Ciçek Wöber-Bingöl
Journal:  J Headache Pain       Date:  2010-12-18       Impact factor: 7.277

9.  Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients.

Authors:  Il Han Yoo; WooJoong Kim; Hunmin Kim; Byung Chan Lim; Hee Hwang; Jong Hee Chae; Jieun Choi; Ki Joong Kim
Journal:  J Clin Neurol       Date:  2017-07       Impact factor: 3.077

10.  Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giulia Serra; Giovanni Dominici; Juliana Fortes-Lindau; Monica Pastina; Ludovica Telesforo; David Lester; Paolo Girardi; Roberto Tatarelli; Paolo Martelletti
Journal:  Patient Relat Outcome Meas       Date:  2010-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.